Visit coronavirus.gov for the latest Coronavirus Disease (COVID-19) updates.

Office of Disease Prevention and Health Promotion

Search HealthyPeople.gov

Search form

Print Icon Print

You are here

Home » 2020 Topics & Objectives » Immunization and Infectious Diseases » IID-4.2 Data Details

IID-4.2 Data Details

Expand All

IID-4.2 Reduce new invasive pneumococcal infections among adults aged 65 years and older

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

Data Source: 
Active Bacterial Core Surveillance
Bridged-race Population Estimates
Changed Since the Healthy People 2020 Launch: 
Yes
Measure: 
per 100,000
Baseline (Year): 
40.7 (2008)
Target: 
31.0
Target-Setting Method: 
Projection/trend analysis
Target-Setting Method Justification: 
Whenever possible, the assumptions used in the analysis were based on published data. The effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13, licensed in February 2010) was assumed to be similar to that of the 7-valent pneumococcal conjugate vaccine (PCV7, licensed in 2000). Also, invasive pneumococcal infections caused by strains not covered by PCV13 were assumed to increase modestly. Estimates were adjusted to account for the lower proportion of pneumococcal infections caused by PCV13 strains, compared with the proportion covered by PCV7 before that vaccine was introduced. When published data were not available, assumptions were based on data available from CDC (www.cdc.gov/ABCs).
Numerator: 

Number of persons aged 65 years and older with a laboratory-confirmed invasive pneumococcal infection in the past 12 months

Denominator: 

Number of persons aged 65 years and older

Comparable Healthy People 2010 Objective: 
Retained from HP2010 objective
Data Collection Frequency: 
Annual
Methodology Notes: 

    An invasive pneumococcal infection is defined as a laboratory-confirmed isolation of Streptococcus pneumoniae from a normally sterile site (blood, cerebral spinal fluid, etc.).

    FOR SINGLE DATA YEARS: Case rates are calculated based on the resident population of the ABCs surveillance areas for the data year involved. For census years (e.g. 2010), population counts enumerated as of April 1 are used. For all other years, populations estimates as of July 1 are used. Postcensal population estimates are used in rate calculations for years after a census year and match the data year vintage (e.g. July 1, 2010 –July 1, 2011 resident population estimates from Vintage 2011 are used as the denominator for 2011 rates). Postcensal population estimates are used in rate calculations for the years between censuses (e.g. 1991-1999, 2001-2009). Race-specific population estimates for 1991 and later use bridged-race categories. Missing race data was multiply imputed and surveillance rates were standardized to the racial distribution of the US population using the NCHS bridged-race vintage 2010 postcensal file.

Caveats and Limitations: 
Cases with missing race data were multiply imputed using sequential regression imputation methods. ABCs Areas California (San Francisco County and children

Revision History

Any change to the objective text, baseline, target, target-setting method or data source since the Healthy People 2020 launch.

Description of Changes Since the Healthy People 2020 Launch: 
In 2014, Population Estimates was added as a data source to reflect measure's population denominator. The data and target were not revised. In 2015, the denominator data source name was revised from Population Estimates to Bridged-Race Population Estimates for Census 2000 and 2010. The numerator data source, baseline estimate, target, and target-setting method remain unchanged.

References

Additional resources about the objective

  1. Centers for Disease Control and Prevention (CDC). Active Bacterial Core surveillance (ABCs).
    https://www.cdc.gov/abcs/
View Data Details for all objectives in Immunization and Infectious Diseases